ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer Clinical Trial

Official title:

Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06366347
• Other study ID #: 23-695
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 2024
• Est. completion date: March 1, 2029

Study information

• Verified date: April 2024
• Source: Dana-Farber Cancer Institute
• Contact: Panagiotis Konstantinopoulos, MD, PhD
• Phone: 617-632-2334
• Email: Panagiotis_Konstantinopoulos[@]DFCI.HARVARD.EDU
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for two years. This treatment regimen has shown benefit in terms of delaying cancer progression in prior clinical trials, but the benefit of the pembrolizumab maintenance treatment and whether all participants need it is unclear. This research is being done on the maintenance portion of treatment to compare the efficacy between the combination of letrozole + abemaciclib and pembrolizumab alone following chemotherapy and pembrolizumab.

The names of the study drugs involved in this study are:

• Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor)

• Letrozole (a type of aromatase inhibitor)

• Pembrolizumab (a type of monoclonal antibody)

Description:

This is a randomized, phase 2 trial of maintenance letrozole + abemaciclib vs. pembrolizumab after carboplatin + paclitaxel + pembrolizumab chemotherapy in participants with advanced or recurrent estrogen receptor (ER) positive (ER+), mismatch repair proficient (MMRP), TP53 wild-type endometrial cancer.

Participants will be randomized in one of two study groups: Abemaciclib + Letrozole vs. Pembrolizumab. Randomization means that a participant is placed into a study group by chance.

The U.S. Food and Drug Administration (FDA) has not approved abemaciclib, letrozole or pembrolizumab for endometrial cancer but they have been approved for other uses.

The research study procedures include screening for eligibility, study treatment visits, X-rays, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, Positron Emission Tomography (PET) scans, blood tests, and electrocardiograms (EKGs).

Participants will be administered study drugs for up to 2 years and will be followed for 3 years after completing study treatment.

It is expected that about 76 people will take part in this research study.

Eli Lilly is supporting this research study by providing funding and the study drug abemaciclib.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 76
• Est. completion date: March 1, 2029
• Est. primary completion date: September 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must have histologically confirmed either i) endometrioid endometrial cancer or ii) endometrial carcinosarcoma with endometrioid epithelial component.

• Participants must have ER-positive disease, defined as = 1 percent of tumor cell nuclei being immunoreactive by immunohistochemistry (IHC). If multiple analyses have been performed, judgment should be based on the most recent biopsy or pathology specimen analyzed in a CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory.

• Tumor must be TP53 wild-type as determined by immunohistochemistry (IHC) or via CLIA-certified targeted Next-Generation Sequencing (NGS); IHC assessment of p53 status is included in the NCCN guidelines of uterine neoplasms for the molecular analysis of endometrial carcinoma.

• Participants must have mismatch repair proficient (MMRP) endometrial cancer as determined by immunohistochemistry (IHC) or polymerase chain reaction (PCR) or any CLIA-certified next generation sequencing assay.

• No known tumor mutational burden = 10 mutations/megabase (Mb).

• Participants must have completed a minimum of 4 cycles and a maximum of 10 cycles of combination carboplatin, paclitaxel, and pembrolizumab.

• Participants must be considered appropriate to proceed with maintenance pembrolizumab monotherapy.

• Participants must have had measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.

• Participants are permitted to have received:

• a. Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin])

• b. Prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/paraaortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must have been completed at least 4 weeks prior to registration.

• c. Prior hormonal therapy for treatment of endometrial cancer.

• Must be able to initiate study drug between 3 to 8 weeks (or 21 to 56 days) after completion of their final dose of chemotherapy and pembrolizumab.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix A)

• Age = 18 years

• Participants must have normal organ and bone marrow function within 2 weeks before starting protocol therapy as defined below:

• System Laboratory Value

• Hematologic

• ANC =1.5 × 109 /L

• Platelets =100 × 109 /L

• Hemoglobin =8 g/dL Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.

• Hepatic

• Total bilirubin =1.5 × ULN Patients with Gilbert's syndrome with a total bilirubin =2.0 times ULN and direct bilirubin within normal limits are permitted.

• ALT and AST =3 × ULN

• Creatinine = 1.5 × institutional ULN, OR

• Creatinine clearance = 60 mL/min/1.73 m2 for participants with creatinine levels above 1.5 x institutional ULN.

• Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; ULN = upper limit of normal.

• Ability to understand and the willingness to sign a written informed consent document.

• Ability to swallow and retain oral medication.

• Participants must have archival tissue available for analysis in the form of a formalinfixed paraffin embedded (FFPE) block or unstained slides. Note: confirmation of availability of archival tissue is the only requirement for eligibility, archival tissue does not need to be received by the study team prior to enrollment.

Exclusion Criteria:

• Participants who have received previous treatment with CDK4/6 inhibitors, including but not limited to previous abemaciclib therapy.

• Any gastrointestinal dysfunctions that could interfere with the absorption of study drugs (e.g., bowel obstruction, inability to swallow tablets, malabsorption syndrome, unresolved nausea, vomiting, diarrhea CTCAE v 5.0 > grade 1).

• Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade =1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization.

• The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.

• Major injuries or surgery within 14 days prior to randomization and/or planned major surgery during the on-treatment study period. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization.

• Other malignant disease with disease-free = 3 years except: curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, or ductal carcinoma in situ (DCIS) of the breast or any other cancer deemed by the investigator to be at low risk for recurrence of that malignancy.

• Active brain metastases (e.g., stable for < 8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsant therapy. Corticoid therapy is allowed if administered as stable dose for at least 1 month before randomization).

• Females who are pregnant or lactating. The effects of the study agents on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use a medically approved contraceptive method during the treatment period and for 3 months following the last dose of study agent. Contraceptive methods may include an intrauterine device (IUD) or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. A negative serum pregnancy test is required for study entry from women of childbearing potential.

• The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease/pneumonitis, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).

• Participants who at the time of study enrollment are known to require concomitant therapy with strong CYP3A4 inducers, or strong inhibitors of CYP3A4. Due to potential drug interactions, concomitant use of these medications is not permitted for the duration of treatment on trial. Participants are eligible for study entry if an appropriate substitution is made prior to the first dose of study medication.

• Participants with personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.

• Individuals with a history of a different malignancy are ineligible with the following exceptions: individuals who have been treated and are disease-free for a minimum of 3 years prior to study enrollment, or individuals who are deemed by the treating investigator to be at low risk for disease recurrence.

Related Conditions & MeSH terms

• Endometrial Cancer
• Endometrial Neoplasms
• Recurrence
• Recurrent Endometrial Cancer
• TP53

Intervention

Drug:
• Abemaciclib
CDK inhibitor, tablet taken orally per protocol.
• Letrozole
Aromatase inhibitor, tablet taken orally per protocol.
• Pembrolizumab
Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Dana-Farber Cancer Institute at Foxborough	Foxboro	Massachusetts
United States	Dana-Farber Cancer Institute at Milford	Milford	Massachusetts
United States	Dana-Farber Cancer Institute at South Shore Hospital	Weymouth	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median Progression Free Survival (PFS)	PFS is defined as the time from the date the participant was randomized to the date of documented progressive disease (PD) by RECIST version 1.1 or death (regardless of cause) in the absence of progression, regardless of whether the participant withdraws from study drug or receives another anti-cancer therapy prior to progression. Participants alive without disease progression are censored at date of last disease evaluation. A participant who dies without progression, and the death is >12 weeks after the last evaluable tumor assessment, is censored for PFS at the date of last disease evaluation. A participant who has no baseline or no post treatment tumor assessment is censored at 0 days for PFS, unless she dies < 12 weeks from randomization, in which case the PFS event date is the death date. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum, taking as reference the smallest sum on study with at least 5 mm absolute increase.	Up to 2 years
Secondary	Grade 3-5 Adverse Events (AE) Rate	Grade 3-5 AE rate is defined as the proportion of patients who experience a grade 3-5 adverse event based on the Common Toxicity Criteria for Adverse Events version 5.0 as reported on case report form.	Up to 2 years and 1 month
Secondary	Median Overall Survival (OS)	OS is defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive based on Kaplan-Meier methodology.	Up to 5 years
Secondary	Objective Response Rate (ORR)	The percentage of participants who achieved complete response (CR) and partial response (PR) based on RECIST 1.1 criteria. Complete Response (CR) for target lesion: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to < 10 mm. Partial Response (PR) for target lesion: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.	Up to 2 years